International Journal of Antimicrobial Agents 2000: Vol 16 Table of Contents

9 Pages·2000·1.7 MB·English

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents
International Journal of Antimicrobial Agents 16 (2000) 565—571
www.ischemo.org
Volume contents
Volume 16 (2000)
No. 1
Leading Article
Genetic tools for the simultaneous identification of bacterial species and their antibiotic resistance genes: impact on
clinical practice
SS ME oe a Oe ee Re Ee EE ee 6 eae See ee ote i ee l
Review
The fluoroquinolone antibacterials: past, present and future perspectives
og Se rere ere ee err ors eT ee es eer RP he er ee he 5
Original Articles
Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean
countries
ma. wecenes, FP. App aed LAGER Shay TO «gc. ook eas eo eek Ee Oe a 8 2 17
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and
Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines
ZZ, cee, Be Tees. FT. eee Ge Be 8k ke. ho 5 we Rh eS 4 CEESwe e e 25
Spectrum and transferability of B-lactam resistance in hospital strains of Enterobacter isolated in Bratislava and
Innsbruck
H. Bujdakova, J. Klimaékova, F. Allerberger, M. Moravécikova, M. Bagova, J. Hanzen, D. Michalkova-Papajova, M.P.
ee a: TE a ck Pe ak oe ok SER RRS PROD OE ae ee ee oe nee 3]
Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS
J.C. McNabb, R.C. Owens, D. Xuan, R. Quintiliani, C.H. Nightingale and D.P. Nicolau... ......0.0..2004 4 37
The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers
ae. &. Eee, Be Ca, A GI Oe Bh a a ee ee Ewe ee ea 45
Commentary
The millennium bugs — the need for and development of new antibacterials
es es Fen IE A Py oe EER EES eS Ee eS 8 OES He EO 5]
Short Communications
In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis
ee. eee NE Ee. Fe ike 8 sok ee RR ee ea ke Be See ee ee 61
Antibiotic resistance among enterococcal strains isolated from clinical specimens
a ee NE F. 6 66 ek SRS ee ee a eee i OR A ew ee 65
Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis
Be. ¥, pettenconrt,.5:. Bee- te a G.I 6 a re 8 ee EES FEES ee eee) 69
Propyl gallate increases in vitro antifungal imidazole activity against Candida albicans
y. sired, FD. D Auria, M. Teeca, A. Cater ae G. SIR gk ee ee eee ees Res 73
566 Volume Contents vol. 16 (2000)
Letters
Antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Istanbul
a 0 oe et a a a el eo ae ae tr eee aed te RR ea ane al 77
o£ 6 +7 eas
The relationship between resistance in bacteria and antibiotic use in neurology and haematology units
pe ee, gk a bp ak AA A ee a EER Oe ee EE Se we ROE 79
I or aca Ae, he ee Ee re Be eo ee al ag A ate ig 81
No. 2
Editorial
NS Moc eens eer a a a Get eee pg ee eee SE he CEP SER ew EPA 83
Introduction
Febrile neutropenia: a necessary evil?
a ET ee ESTAS Dead RRM ae ap eee a” PU eo ene SO me ee ae ee rae A 85
S ee Boe SS
Original Articles
Laboratory diagnosis of infections in febrile neutropenic or immunocompromised patients
RN ae Bars eae SWAN igs wa a a ak a eae ek a Bae ny Benge ae, Weo h gla s Ban el awe ap 87
Radiological and invasive diagnosis in the detection of pneumonia in febrile neutropenia
ae es at nh a Bh eda ae Salient eras bee en Unt e oe rhe eet Qn ee gp ate eee Ae 9]
eS 2 ae & FS -38
Unusual presentations of infection in neutropenic patients
rs ee ac ew a ee a ete See aR gt ad Pe ea Ss eae ee ep 4
, 2 eS ee
New pathogens in neutropenic patients with cancer: an update for the new millennium
I aa Si ig a Ns DAE Re En amu ea) Te IN i te a Ee ee dog eps 97
ns & Se
Therapeutic guidelines for Pseudomonas aeruginosa infections
i cc 412 8S Co seinen Oo ee oe Nila ar em ee ee elke Ea a es AR Oo ae kere 103
ee eee es
Risk factors assessment in febrile neutropenia
eae MT ata eS NPE NeS ee” ge PO cr OO ae Ce 107
o. @).0 £°4 -* @
Prediction of neutropenia
RESET Rae ae ee Bake mg me ee er ae a aee a cera eae SR Se oe ee ee
Colony stimulating factors in patients with fever and neutropenia
I a sick Tage a AC a na gl a ath ea tg Sra a TM ee ee oe ath og 117
a ee a
Antibacterial prophylaxis
i OE a AC Stair ie ae Ok! Lf Paha ne go Mh Bar UE Cee nde al eed oc mh lo I
Febrile neutropenia: antifungal prophylaxis
a a a ud Ba Se ee RO Oe ALLY FORE ES ES OO
Empirical treatment of sepsis in neutropenic patients
ei a eee ee ee we POOR CS ee re OF Pre ee Pel Tee ea So
Management of fungal infections in neutropenic patients: more doubts than certainties?
ee ee RS gy oko be we i ee Pe ee a ee Pe sea,
ea ae ee
Modifications of therapy
ea Ge a hae A Oy ee ee a a ee ay ae a ee OR See
Standard antifungal therapy in neutropenic patients
i SG aS SR a eT PRS 2 eR a, VRE ee 143
. 2 2 h ew OB
Volume Contents vol. 16 (2000) 567
New antifungal agents and preparations
ee 5a ek. OK Raed eck Be wl a a ee Gs ea a ee ee ae Se oe 147
Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
or. Se, Ee. FO, Be. Fe GO kk Ee a oD A ek i ae ee 151
Antiviral therapy of herpes simplex
i I 6 ia 8 ae BAD 6 EER eR AE Ow LE a Be ae i ee ee 157
Prevention and management of mucositis in patients with cancer
Fe is bes oe Dace EE OES Aw Rw he ee AK Ble ee a aa ee 161
be oR eS SE ee ae a ee ee ee ee a ak ee eee 165
Out-patient management of febrile neutropenia
i Es 5 68 le BAe Ok RESP ESE EEE EES Ree ee ee 169
Febrile neutropenia in children
PT sudo) & Oe Ak eee 2 ee a ee i a be 173
Febrile neutropenia in allogeneic transplantation
ee ee ee es Ts ik ee ee Re Ee es 4S Le ew ee ee 177
UE og eg ga Eb we OS Ok We ARE Fee F 6 aE ee ee ee ee 18]
Tg gra ghia tg Merah aih ig) a la nce etd Oea LUT Soe i itn amc ee Lae eee ager ae ie ee 185
189
No. 3
Review
Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent
problem
ee a Fre ON cai Ree ee Rk we ®t ows ed ee ee ee 191
Commentary
Licensing new antibacterial agents —- a European perspective
PL IS bee ee AE i ee we ee a a RO ORS ee ee se Cae ae Ot ek ae aoe ee 199
Original Articles
Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984
Pm £00; DB. Fees, AA: Ge, Gl, FO GE 6 PO on 0 ERE BAAS A ee oe es 205
Natural antibiotic susceptibility of Sa/monella enterica strains
oy ee a IIE v.60 5 a ae ee ne ae ee oe ee ae Se he ek ae 211
Mediterranean clone of penicillin-susceptible, multidrug-resistant serotype 6B Streptococcus pneumoniae in Greece, Italy
and Israel
G.A. Syrogiannopoulos, F. Ronchetti, R. Dagan, I. Grivea, M.P. Ronchetti, N. Porat, T.A. Davies, R. Ronchetti, P.C.
SS Ge Fa SU a Ee EE a wa ee Ee OE Ee es owe 4 es
In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria
R. Schaumann, G. Ackermann, B. Pless, M.C. Claros, E.J.C. Goldstein and A.C. Rodloff.......0.0.0....040485
Outer membrane changes in Pseudomonas stutzeri resistant to chlorhexidine diacetate and cetylpyridinium chloride
UV. Fanart, J.-F. alee, ¢.K. Feet Oe AD. FO ok PERRAK SEw E Y Bed
568 Volume Contents vol. 16 (2000)
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin
against uropathogens cultured from patients with complicated urinary tract infections
ee a a I I Og gk ee ees Oe ee ee ee ee ey Oe OS 239
Short communications
Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period
M. Ferrero, J.A. Ducons, B. Sicilia, S. Santolaria, E. Sierra and F. Gomollon 245
Decrease of antibiotic resistance in Salmonella typhi isolated from patients attending hospitals of Dhaka City over a 3
year period
S.M. Zahurul Haque Asna and J. Ashraful Haq 249
Correspondence
A 10 year study of resistance of Staphylococcus aureus 10 selected antimicrobials in three Venezuelan Centre
A.J. Rodriquez, C.N. Rodriquez, P. Meijomil, A. Garcia, C. Duque, M. Molina... 1... 0.0... 000.0 eee. 253
First report of ampicillin and glycopeptide resistant Enterococcus faecium VanA bacteraemia in Greece
G. Kouppari, H. Papadaki, C. Arida, J. Sakellariou, N.J. Legakis, J. Papaparaskevas .. 1... 0. 2 0 ee ee 254
Special Section
International Meeting on Antimicrobial Chemotherapy in Clinical Practice ACCP
Respiratory Tract Infection
Epidemiological survey of bacterial resistance in upper respiratory tract infections in Italy
SS 2 eons ty 4 6 ae ee ee RR ea eek awe 0 bk AES Oe ee Ee A 259
New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
263
Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations
of chronic bronchitis treated with a fluoroquinolone
i Aree, #.me. Feet, 4. Forres, B Cae GRE EF. TO on eh eee eee eas 273
The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia
ee es Ore De Es gi a eh eR he eM Oe eR 281
What’s new in streptococcal pharyngitis
a ge ee GS gk eK pO eS OR Be ee 3 Be SR ee a es
Antibiotic Usage
The role of the hospital pharmacist in cost control and antibiotic policy
ie I Ns eg ear hc ak ak acgs Geel a ar ceri ra mie see al he kMa og yg ce tw aad ak GeB e eeB i Rn eR
Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy
M. Bassetti, A. Di Biagio, B. Rebesco, G. Cenderello, M.E. Amalfitano and D. Bassetti... 1... 0.0 ee eee.
Sequential or switch treatment — which criteria should be fulfilled?
I CE Mi eee e a a re Rae a gh Io) eee Se Ae a regi ss ele ee ag le al ee a gas Melk ee ee ete 301
The role of antimicrobial policies in neutropenic patients
ay ee oh ce Se Ria ae a God eh gy on ee Nahe ee OA RA ORS A 303
Antibiotic usage and resistance — trends in Estonian University Hospitals
ire re en I > ee elon ei RAO ia lee We Oh ee ME a ig Re 309
Antifungal Drugs
Current and future antifungal therapy: new targets for antifungal therapy
Ee aa At oe ate a Ye Gre ee Ae) gta ely ee gre gw iatC al 5 cde ge a Sg tg eG ee We AT Gl Bt tay 317
Making the diagnosis of fungal infection: when to start treatment
a ee OG Lee Wa ere ee ep le ae a eal gas ek ge el re beo ta eea ie S
Volume Contents vol. 16 (2000) 569
Mechanisms and clinical significance of antifungal resistance
RS 4k we a 8 La a oR A Ba ae onal 331
Miscellaneous topics
Emerging and reemerging pathogens
im, copies Lin, #. Tel, £. Cae ©. Se ee ©, i og ae ea Re iw aw be ike eee MER 335
Anaerobic infection therapy
FE Te ee Ce ee LS ne Oe es Tee 341
Ciprofloxacin versus chloramphenicol in the treatment of salmonella infection
er eT MI tan, I, 6 86 6k ae a he ae ee 347
Virological infections
Does HGV—HIV co-infection exist?
E. Pontali, P. Pedemonte, M. Bassetti, 5. Boni and BD. Bassetthl.. oo. tc cee we eee ewe eben 349
Cellular factors involved in the induction of resistance of HIV to antiretroviral agents
rs Sears Sie: Ae NI ts <I ia 5 a ae a re A ke ies ie cab gcle ceria ig ne ee 353
Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects
K. de Gaetano Donati, S. Bertagnolio, M. Tumbarello, E. Tacconelli, M. Cataldo, B. Longo and R. Cauda...... 357
Tolerance of highly active antiretroviral therapy in HIV patients: a 3-year follow up
A. Beltrame, V. Del Bono, M. Marturano, P. Pedemonte, R. Rosso, G. Mazzarello, M. Bassetti, A. Collida, F. Fusco
I Sg ov wh Rae RRR ACRE OD EXE SELES KEARSE LE Cee Chee eee eee 361
Analysis of drug costs in a domiciliary care unit for AIDS patients: a 3-year survey
A. Beitrame, D. Gori, F. Marenco, D. Bassetti and F. Hemrigatt on ee ee ewe thas eee. 363
Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors
P. Fiore, E. Donetti, 5. Boni, E. Ponta, R. Tramatodl and D. Basel. ww ee eee ee 365
Compliance to combination antiretroviral therapy in HIV-1 infected children
a. oem, £. Poul, &. Oe Go, F. Peete onl ©. BO. wk ce ee a ee ew ee wee eN 371
Response-adjusted «-interferon therapy for chronic hepatitis C in HIV-infected patients
T. Prestileo, G. Mazzola, F. Di Lorenzo, P. Colletti, F. Vitale, D. Ferraro, R. Di Stefano, C. Camma and A. Craxi 373
NN IA I a no he we tw ee ck oe a ie ee ot Bas be ee ee eee 379
No. 4
Review
Methylene blue derivatives — suitable photoantimicrobials for blood product disinfection?
an SO 5. Sak 4 a 6 BR HS 0A oe PKS OEE EE Ee eR ek eee eee ee 381
Original Articles
B-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing f-lactamases of gram-negative
extraintestinal clinical isolates
Z. Gal, D. Szabo, P. Kovacs, F. Hernadi, B. Toth-Martinez and F. Rozgonyi... 1... 1... ee eee e eee ww ne 395
Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997—1998
E. Huczko, B. Conetta, D. Bonner, L. Valera, T. Stickle, A. Macko and J. Fung-Tome .. 1... 0.00 0 ee ee ee 401
Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC
breakpoints and doses
Ae. Fae, Ze eee. 5. 2, See eee a, FO Ck ok 6 ak Ee be A AO OR A ES 407
Letter
Studies on the genotoxicity of turmeric extracts in bacterial system
De Per Oe Be BR % 6a RS ee NCES EA ORR De eR EERE OEE EAE 415
570 Volume Contents vol. 16 (2000)
Special Section
International meeting on Resistance to Antimicrobial Agents (RAA)
New concepts for future control of HIV derived from studies of pathogenesis
421
Clinical impact of antiretroviral resistance testing: current problems and future directions
ee hg bk a gg Dae a a Oe ee be ae Pea ee Oe OG Se ae ee ee 425
Resistance to antiretroviral drugs in patients with primary HIV-1 infection
B. Brenner, M.A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R.-P. Sekaly, B. Conway, J.-P. Routy and
mrerionsives at Hae Geet PAY TORII TO cei hae ee wee wee ewes 429
Genotyping in HIV drug resistance mutations: epidemiology in 145 patients
M. Rosina, V. Micheli, S. Besana, C. Toia, M.R. Gismondo and A. Cargnel. .. 2... 6 ee 435
Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure
J. Schiipbach, Z. Tomasik, D. Nadal, B. Ledergerber, M. Flepp, M. Opravil and J. Boni... .........004.4. 441
Laboratory diagnosis of human cytomegalovirus (HCMV) central nervous system disease in AIDS patients
ne I sal de a tes een te Wie anal fe ary ww eRe age eng ws NR sg a ek 6 a eR we a Mee A’ 447
Use of CMV transcripts for monitoring of CMV infections in transplant recipients
ee, os Sn a. I OI fare a ake kk ee Oa le te be em ele ee 455
Cytomegalovirus pp65 antigenemia in HIV patients: retrospective on 3 years study
A. Lombardi, L. Drago, M.R. Bartolone and M.R. Gismondo .... 1... 0. cc ee es 461
Epidemiology of HIV-1 and emerging problems
r.. Lees, A. a ends, 52. ae Fone ae J. GOD gnc i ee meee eee wena 463
Bacterial agents of lower respiratory tract infections (LRTIs), B-lactamase production, and resistance to antibiotics in
elderly people
C.M. Sanguinetti, F. De Benedetto, G. Miragliotta and DEDALO Study Group... 1... 0. 6 ee 467
Antibiotic resistance in Gram-positive cocci
-. Rea, G. Ba Ge A; TIE oo aon OR Re ee bw eee HO 473
Epidemiology of Gram-negative antibiotic resistance in outpatients: a year of surveillance
L. Drago, B. Mombelli, E. De Vecchi, L. Tocalli, G. Nardi and M.R. Gismondo .. 1... 00 0 0 ee 479
Resistance of bacteria in urinary tract infections
eS 57 GhS k cua eew ah ob ee che gla ate eb A a ele AOR Wak ee Aa oe OS oe a 483
The impact of resistance on the management of urinary tract infections
NR Soa go SIE SN ee Ce ee wg et a ek ae ane eh a a a, Re Be AR A a: 489
Changes in the resistance patterns among upper respiratory tract infection pathogens
ke Ra Pala eg Send 6 Oa eM eas ta Ta Cag eg ae eae age ere ale Naren Ta Eye ee wns 493
Short-course treatment for acute tonsillopharyngitis
ye ee a a kk ae SCR RY 8 ae ee ed ee a aw EES 495
New technologies and applications of PCR in clinical diagnosis
ORES A ty ae ae ee. Se Narn Ue ct a Oea e ne ee Fa oe a Re re are an aso e ae ere 499
Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics
Fe Rg a re ee ee ee ae ee ee re es ee ee 501
Strategies to treat patients with antibiotic resistant Helicobacter pylori
I 607 Ris ike PE a eC od a hia ees pe Sad cal eck be aig cee Sais gl gt a dsa ieg le Tats o GAR Sle ON GRE 507
Volume Contents vol. 16 (2000) 571
The intensive care physician and control of antimicrobial resistance
ee OU GE Wis OY bok bea ae G4 OS AEE Pe aoe eS Cae ee ena ks S11
Iron deficiency anaemia and Helicobacter pylori infection
B. Annibale, G. Capurso, G. Martino, C. Grossi and G. Delle Fave... 1...ee 515
Treatment and prevention of antibiotic associated diarrhea
E. Bergogne-Beérézin 521
oe ££ 6 &@ 6} 4&2 Oe Oo Ge Oe HS BS OV Se oe Se He OOK UH OS USD HERS SO Ue US Se OM OU SD OCS Se DO RS OOS CO OSS RS GS SSD
Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic
os ee. bey Se Ce Fy PE ko Sa GEOR OER 8 A ESS AE PR OE MER I 527
The use of probiotics in medical practice
ee GE Fre: Ie oie ee Rw ee EG Ae Fe ES Rae eee 531
Is there in vivo—in vitro correlation between antifungal susceptibility, species of Candida spp. and clinical outcome?
V. Kremery Jr... 537
e &¢ 6 @ 6S A & OS eR SOS) Ot COP SE SS 2 SOS eS ES SS OS SH SS eS. Se DS SHO OS SS. OS Owe LS eS ee eS Oe Se ee Se
Antifungal therapy in thoracic cancer patients with low dose liposomal amphotericin B (AmBisome)
c. See, 4. Gea, Fa ee FE Gs ki eo a a a es 2 OES 541
Candida albicans cellular internalization: a new pathogenic factor?
L. Drago, B. Mombelli, E. De Vecchi, C. Bonaccorso, M.C. Fassina and M.R. Gismondo ................ 545
Pneumocystis carinii diagnosis: an update
F. Agostoni, C. Atzori, E. Angeli, A. Mainini, V. Micheli and A. Cargnel ... 1... 0... cc ee ee 549
Author index. ..... 559
rs fe oe eS ee eR Se ES Re es De Se PD) OD SS OS SS DS DB O°. Ro Oo 8. oe STS SOS. SH UD AE Ee eS: 8 Re Ce OR ee ee eS Se OU Ee
Volume contents... . 565
Instructions to authors 573
oe PR ©@ He ELA ES 48 Hh RC UR CO SE Ee eS Se BOR SE BO. OOH SG SOR Se eH Oe OS OS. ORO SD? 2S we FO SS SS Ge